Skip to content

Intercept Pharma: Buy ahead of earnings: Jefferies

July 29, 2017

Jefferies analyst, Michael Yee, reiterated his Buy rating on shares of Intercept Pharmaceuticals (NASDAQ: ICPT) ahead of earnings and suggests buying shares ahead of the event. The company reports EPS on July 31 and the analyst thinks Ocaliva sales could beat consensus and new positive Phase II data in new PSC indication (upside, not in consensus ests) is possible as well as clean Phase II lipid data in NASH (supports good safety in NASH), which are due in mid-17.

The analyst stated “we continue to like ICPT higher through 2018 on continued launch execution including EU and into major Phase III NASH data by 2019, which should be positive”.


From → Uncategorized

Leave a Comment

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s

%d bloggers like this: